Clovis/Qiagen to adapt approved diagnostic as companion for lung cancer drug
This article was originally published in Scrip
Executive Summary
Clovis Oncology has signed an agreement with Qiagen to develop a companion diagnostic test for its promising drug candidate, CO-1686, in development as a treatment for non-small cell lung cancer (NSCLC).